WO2018169307A1 - Procédé de concentration microbienne au moyen de diatomite et procédé d'extraction d'acides nucléiques - Google Patents
Procédé de concentration microbienne au moyen de diatomite et procédé d'extraction d'acides nucléiques Download PDFInfo
- Publication number
- WO2018169307A1 WO2018169307A1 PCT/KR2018/002994 KR2018002994W WO2018169307A1 WO 2018169307 A1 WO2018169307 A1 WO 2018169307A1 KR 2018002994 W KR2018002994 W KR 2018002994W WO 2018169307 A1 WO2018169307 A1 WO 2018169307A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- dimethyl
- composition
- diatomaceous earth
- silane compound
- Prior art date
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 79
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 79
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 35
- 238000000605 extraction Methods 0.000 title claims abstract description 31
- 230000000813 microbial effect Effects 0.000 title claims abstract description 23
- 244000005700 microbiome Species 0.000 claims abstract description 76
- ZLFRJHOBQVVTOJ-UHFFFAOYSA-N dimethyl hexanediimidate Chemical compound COC(=N)CCCCC(=N)OC ZLFRJHOBQVVTOJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000005909 Kieselgur Substances 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 55
- -1 silane compound Chemical class 0.000 claims description 54
- 229910000077 silane Inorganic materials 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 38
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 36
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 125000003282 alkyl amino group Chemical group 0.000 claims description 27
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 claims description 22
- LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 claims description 20
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 12
- 230000028327 secretion Effects 0.000 claims description 12
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 claims description 10
- 239000012969 di-tertiary-butyl peroxide Substances 0.000 claims description 10
- MBAXWTVHCRPVFW-UHFFFAOYSA-N methyl 3-[(3-imino-3-methoxypropyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSCCC(=N)OC MBAXWTVHCRPVFW-UHFFFAOYSA-N 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 210000002700 urine Anatomy 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- PHQOGHDTIVQXHL-UHFFFAOYSA-N n'-(3-trimethoxysilylpropyl)ethane-1,2-diamine Chemical compound CO[Si](OC)(OC)CCCNCCN PHQOGHDTIVQXHL-UHFFFAOYSA-N 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 5
- GHNFXFCVNHUNQY-UHFFFAOYSA-N 2-n-(2-aminoethyl)-5-trimethoxysilylpentane-1,2-diamine Chemical compound CO[Si](OC)(OC)CCCC(CN)NCCN GHNFXFCVNHUNQY-UHFFFAOYSA-N 0.000 claims description 3
- TZAKHNORFOVVDL-UHFFFAOYSA-N 6-triethoxysilylhexan-1-amine Chemical compound CCO[Si](OCC)(OCC)CCCCCCN TZAKHNORFOVVDL-UHFFFAOYSA-N 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 210000003608 fece Anatomy 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 210000002751 lymph Anatomy 0.000 claims description 3
- 210000002381 plasma Anatomy 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 claims description 3
- PFYBXKBLFFEPRJ-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN.CO[Si](OC)(OC)CCCN PFYBXKBLFFEPRJ-UHFFFAOYSA-N 0.000 claims description 2
- KFOFUMHUCBFQOF-UHFFFAOYSA-N 4-triethoxysilylbutan-1-amine Chemical compound NCCCC[Si](OCC)(OCC)OCC.NCCCC[Si](OCC)(OCC)OCC KFOFUMHUCBFQOF-UHFFFAOYSA-N 0.000 claims description 2
- JILBPZJGIGDIGK-UHFFFAOYSA-N 5-triethoxysilylpentan-1-amine Chemical compound CCO[Si](OCC)(OCC)CCCCCN JILBPZJGIGDIGK-UHFFFAOYSA-N 0.000 claims description 2
- ZXPCQVNLPCOWEB-UHFFFAOYSA-N NC[Si](OCC)(OCC)OCC.NC[Si](OCC)(OCC)OCC Chemical compound NC[Si](OCC)(OCC)OCC.NC[Si](OCC)(OCC)OCC ZXPCQVNLPCOWEB-UHFFFAOYSA-N 0.000 claims description 2
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000376 reactant Substances 0.000 claims 2
- BHWUCEATHBXPOV-UHFFFAOYSA-N 2-triethoxysilylethanamine Chemical compound CCO[Si](CCN)(OCC)OCC BHWUCEATHBXPOV-UHFFFAOYSA-N 0.000 claims 1
- JMKSUEDDEFSBKE-UHFFFAOYSA-N 4-[3-aminopropyl(diethoxy)silyl]butan-1-amine Chemical compound NCCCC[Si](OCC)(OCC)CCCN JMKSUEDDEFSBKE-UHFFFAOYSA-N 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 239000000284 extract Substances 0.000 abstract description 5
- 238000011109 contamination Methods 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 34
- 238000002474 experimental method Methods 0.000 description 29
- 239000000243 solution Substances 0.000 description 24
- 244000052769 pathogen Species 0.000 description 20
- 241000589562 Brucella Species 0.000 description 17
- 238000002123 RNA extraction Methods 0.000 description 17
- 238000007400 DNA extraction Methods 0.000 description 14
- 230000001717 pathogenic effect Effects 0.000 description 14
- 238000001190 Q-PCR Methods 0.000 description 13
- 230000035484 reaction time Effects 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000012149 elution buffer Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241000589568 Brucella ovis Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000712461 unidentified influenza virus Species 0.000 description 4
- 241000206761 Bacillariophyta Species 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- 108010067770 Endopeptidase K Proteins 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001909 effect on DNA Effects 0.000 description 2
- 230000002681 effect on RNA Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- GHNFSOMFXGUERP-UHFFFAOYSA-N NCCC[SiH2]C(OCC)OCC.C(C)O[SiH](C)OCC Chemical compound NCCC[SiH2]C(OCC)OCC.C(C)O[SiH](C)OCC GHNFSOMFXGUERP-UHFFFAOYSA-N 0.000 description 1
- HBNIRLFLNSERJS-UHFFFAOYSA-N NCC[Si](OCC)(OCC)OCC.NCC[Si](OCC)(OCC)OCC Chemical compound NCC[Si](OCC)(OCC)OCC.NCC[Si](OCC)(OCC)OCC HBNIRLFLNSERJS-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- PDDBPPDHEVWBRW-UHFFFAOYSA-N n'-(3-trimethoxysilylpropyl)ethane-1,2-diamine Chemical compound CO[Si](OC)(OC)CCCNCCN.CO[Si](OC)(OC)CCCNCCN PDDBPPDHEVWBRW-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- PZJJKWKADRNWSW-UHFFFAOYSA-N trimethoxysilicon Chemical group CO[Si](OC)OC PZJJKWKADRNWSW-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
Definitions
- the present invention relates to a method for enriching microorganisms and a method for extracting nucleic acids using diatomaceous earth, in particular diatomaceous earth modified with a silane compound.
- Diatoms are unicellular algae that are distributed in various sizes from 2 ⁇ m to 2 mm and are representative phytoplankton commonly found on the earth. Diatoms account for 20-25% of the total primary production of land and 40% of marine biomass production, and have played an important role in ecosystems as marine producers for millions of years.
- microalgae have high photosynthetic efficiency relative to cell mass and are mainly used for the production of lipids, biofuels, and bioavailable resources through culture.
- diatomaceous earth is a natural siliceous material which is a main component of diatomaceous cell membrane, and is known as bio-silica because it is calcined at 450 ° C. and composed of silica-rich silica on the surface.
- the size of the bio-silica is about 10-20 ⁇ m.
- An object of the present invention is a composition for concentrating microorganisms comprising diatomaceous earth modified with a silane compound as an active ingredient, a method and kit for concentrating microorganisms using the same;
- a nucleic acid extracting composition comprising diatomaceous earth modified with a silane compound as an active ingredient, a nucleic acid extracting method and kit using the same;
- it provides a composition for microbial enrichment and nucleic acid extraction, including a diatomaceous earth modified with a silane compound as an active ingredient, a method and kit for extracting nucleic acid from the concentrated microorganism at the same time as the microorganism concentration using the same.
- the present invention provides a composition for concentrating microorganisms comprising diatomaceous earth modified with a silane compound as an active ingredient.
- the present invention provides a method for concentrating microorganisms comprising contacting a sample containing microorganisms with diatomaceous earth modified with the silane compound.
- the present invention also provides a microbial enrichment kit comprising the composition.
- the present invention also provides a nucleic acid extracting composition comprising diatomaceous earth modified with a silane compound as an active ingredient.
- the present invention comprises the steps of (1) reacting by adding a diatomaceous earth modified with a silane compound to the nucleic acid sample to be extracted; And (2) provides a nucleic acid extraction method comprising the step of eluting the nucleic acid from the reaction.
- the present invention comprises the steps of (1) adding and mixing the diatomaceous earth modified with the silane compound to the nucleic acid sample to be extracted; (2) dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS) and dimethyl 3,3'-dithiobis Reacting by adding one or more selected from the group consisting of dimethyl 3,3'-dithiobispropionimidate (DTBP); And (3) provides a nucleic acid extraction method comprising the step of eluting the nucleic acid from the reaction.
- DMA dimethyl adipimidate
- DMP dimethyl pimelimidate
- DMS dimethyl suberimidate
- DTBP dimethyl 3,3'-dithiobis Reacting by adding one or more selected from the group consisting of dimethyl 3,3'-dithiobispropionimidate
- DTBP dimethyl 3,3'-dithiobispropionimidate
- the present invention also provides a nucleic acid extraction kit comprising the composition.
- the present invention also provides a composition for microbial enrichment and nucleic acid extraction comprising diatomaceous earth modified with a silane compound as an active ingredient.
- the present invention comprises the steps of (1) contacting the sample containing the microorganism to the diatomaceous earth modified with the silane compound to concentrate the microorganism; (2) dissolving the concentrated microorganism; And (3) eluting the nucleic acid from the lysate, and providing a method for extracting the nucleic acid from the concentrated microorganism at the same time as the microorganism is concentrated.
- the present invention comprises the steps of (1) contacting the sample containing the microorganism to the diatomaceous earth modified with the silane compound to concentrate the microorganism; (2) dissolving the concentrated microorganism; (3) dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS) and dimethyl 3,3'-diti in the lysate Reacting by adding any one or more selected from the group consisting of dimethyl 3,3'-dithiobispropionimidate (DTBP); And (4) provides a method for extracting nucleic acid from the concentrated microorganism simultaneously with the concentration of the microorganism comprising eluting the nucleic acid from the reaction.
- DMA dimethyl adipimidate
- DMP dimethyl pimelimidate
- DMS dimethyl suberimidate
- DTBP dimethyl 3,3'-diti in the lysate Reacting by adding any one or more selected from the group consisting of dimethyl 3,3'-d
- the present invention also provides a microbial enrichment and nucleic acid extraction kit comprising the composition.
- the present invention also provides the use of diatomaceous earth modified with a silane compound for microbial enrichment.
- the present invention also provides the use of diatomaceous earth modified with silane compounds for nucleic acid extraction.
- the present invention also provides the use of diatomaceous earth modified with silane compounds for microbial enrichment and nucleic acid extraction.
- the present invention relates to a method for concentrating microorganisms and nucleic acid extraction method using diatomaceous earth, conventional methods for detecting microorganisms do not use the entire solution in more than 1 ml of the patient sample, extracting nucleic acids using only a part of them Detection has been performed using this. For large amounts of microorganisms, this is not a big problem, but for small amounts of microorganisms, it is not possible to detect them correctly, which leads to problems in controlling additional infectious diseases. Research is needed. Therefore, the present inventors have developed a technology capable of concentrating microorganisms about 4-8 times using existing diatomaceous earth, and extracting nucleic acids directly using dimethyl adipimidate (DMA). Developed methods. By enabling microbial enrichment and nucleic acid extraction techniques in one tube, it is expected to significantly reduce external contamination, cost, time and complexity.
- DMA dimethyl adipimidate
- Figure 2 shows the results of experimental validation in the pathogen concentration process.
- D diatomaceous earth
- DA diatomaceous earth modified with APTES.
- Figure 3 is the result of optimizing the pathogen concentration experimental conditions by changing the modified diatomaceous earth concentration.
- Figure 7 shows the results of experimental validation in the DNA extraction process.
- D diatomaceous earth
- DA diatomaceous earth modified with APTES.
- D diatomaceous earth
- DA diatomaceous earth modified with APTES.
- RNA extraction experiment 12 is a result of optimizing RNA extraction experiment conditions by varying the concentration of diatomaceous earth (DA) modified with APTES.
- DA diatomaceous earth
- Figure 13 is the result of optimizing the RNA extraction experimental conditions by varying the reaction time.
- FIG. 16 shows experimental results of applying an amine-functionalized diatomaceous earth-based, dimethyl suberimidate assisted system (ADD system) based on RNA extraction from pathogen Brucella sample.
- ADD system dimethyl suberimidate assisted system
- the present invention provides a composition for concentrating microorganisms comprising diatomaceous earth modified with a silane compound as an active ingredient.
- the silane compound may be a compound represented by the following Chemical Formula 1, but is not limited thereto.
- R 1 to R 3 may each be the same or different, either C1 to C4 alkyl or C1 to C4 alkoxy, R 4 is amino (C1 to C10) alkyl, 3- (2-amino ( C1 to C4) alkylamino) (C1 to C4) alkyl or 3- [2- (2-amino (C1 to C4) alkylamino) (C1 to C4) alkylamino] (C1 to C4) alkyl.
- the silane compound is (3-aminopropyl) triethoxysilane (APTES), (3-aminopropyl) trimethoxysilane ((3-aminopropyl) trimethoxysilane), (1 -(Aminomethyl) triethoxysilane ((1-aminomethyl) triethoxysilane), (2-aminoethyl) triethoxysilane ((2-aminoethyl) triethoxysilane), (4-aminobutyl) triethoxysilane ((4- aminobutyl) triethoxysilane), (5-aminopentyl) triethoxysilane, (6-aminohexyl) triethoxysilane, (6-aminohexyl) triethoxysilane, 3-aminopropyl (diethoxy Methylsilane (3-aminopropyl (diethoxy) methylsilane),
- the microorganism may be any negatively charged microorganism such as bacteria, viruses or cells, and more preferably Brucella ovis or para influenza virus (PIV3) described in the embodiment of the present invention.
- PIV3 para influenza virus
- the concentration of the microorganism may be 10 0 cfu / ml to 10 7 cfu / ml, but is not limited thereto.
- the present invention also provides a method for concentrating microorganisms comprising contacting a sample containing microorganisms with diatomaceous earth modified with a silane compound.
- the silane compound may be a compound represented by the following Chemical Formula 1, but is not limited thereto.
- R 1 to R 3 may each be the same or different, either C1 to C4 alkyl or C1 to C4 alkoxy, R 4 is amino (C1 to C10) alkyl, 3- (2-amino ( C1 to C4) alkylamino) (C1 to C4) alkyl or 3- [2- (2-amino (C1 to C4) alkylamino) (C1 to C4) alkylamino] (C1 to C4) alkyl.
- the silane compound is most suitable for (3-aminopropyl) triethoxysilane (APTES) described in the embodiment of the present invention.
- APTES (3-aminopropyl) triethoxysilane
- the sample containing the microorganism is feces, urine, tears, saliva, external secretions of the skin, external secretions of the respiratory tract, external secretions of the intestinal tract, external secretions of the digestive tract, plasma, Serum, blood, spinal fluid, lymph, body fluids and tissues, but are not limited thereto.
- the microorganism may be any negatively charged microorganism such as bacteria, viruses or cells, and more preferably Brucella ovis or para influenza virus (PIV3) described in the embodiment of the present invention.
- PIV3 para influenza virus
- the concentration of the microorganism may be 10 0 cfu / ml to 10 7 cfu / ml, but is not limited thereto.
- the step of contacting the microorganism to the diatomaceous earth modified with the silane compound may be contacted for 20 to 60 minutes, but is not limited thereto.
- the present invention also provides a microbial enrichment kit comprising the composition.
- the kit may further include a buffer solution for adjusting pH required for effective microbial concentration.
- the present invention also provides a nucleic acid extracting composition comprising diatomaceous earth modified with a silane compound as an active ingredient.
- the silane compound may be a compound represented by the following Chemical Formula 1, but is not limited thereto.
- R 1 to R 3 may each be the same or different, either C1 to C4 alkyl or C1 to C4 alkoxy, R 4 is amino (C1 to C10) alkyl, 3- (2-amino ( C1 to C4) alkylamino) (C1 to C4) alkyl or 3- [2- (2-amino (C1 to C4) alkylamino) (C1 to C4) alkylamino] (C1 to C4) alkyl.
- the silane compound is most suitable for (3-aminopropyl) triethoxysilane (APTES) described in the embodiment of the present invention.
- APTES (3-aminopropyl) triethoxysilane
- the composition is dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS) and dimethyl 3,3'-dity It may further include any one or more selected from the group consisting of dimethyl propionimate (Dimethyl 3,3'-dithiobispropionimidate; DTBP).
- DMA dimethyl adipimidate
- DMP dimethyl pimelimidate
- DMS dimethyl suberimidate
- DTBP dimethyl 3,3'-dity
- the nucleic acid may be DNA or RNA, but is not limited thereto.
- the present invention comprises the steps of (1) reacting by adding a diatomaceous earth modified with a silane compound to the nucleic acid sample to be extracted; And (2) provides a nucleic acid extraction method comprising the step of eluting the nucleic acid from the reaction.
- the present invention comprises the steps of (1) adding and mixing the diatomaceous earth modified with the silane compound to the nucleic acid sample to be extracted; (2) dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS) and dimethyl 3,3'-dithiobis Reacting by adding one or more selected from the group consisting of dimethyl 3,3'-dithiobispropionimidate (DTBP); And (3) provides a nucleic acid extraction method comprising the step of eluting the nucleic acid from the reaction.
- DMA dimethyl adipimidate
- DMP dimethyl pimelimidate
- DMS dimethyl suberimidate
- DTBP dimethyl 3,3'-dithiobis Reacting by adding one or more selected from the group consisting of dimethyl 3,3'-dithiobispropionimidate
- DTBP dimethyl 3,3'-dithiobispropionimidate
- the silane compound may be a compound represented by the following Chemical Formula 1, but is not limited thereto.
- R 1 to R 3 may each be the same or different, either C1 to C4 alkyl or C1 to C4 alkoxy, R 4 is amino (C1 to C10) alkyl, 3- (2-amino ( C1 to C4) alkylamino) (C1 to C4) alkyl or 3- [2- (2-amino (C1 to C4) alkylamino) (C1 to C4) alkylamino] (C1 to C4) alkyl.
- the silane compound is most suitable for (3-aminopropyl) triethoxysilane (APTES) described in the embodiment of the present invention.
- APTES (3-aminopropyl) triethoxysilane
- the nucleic acid may be DNA or RNA, but is not limited thereto.
- the present invention also provides a nucleic acid extraction kit comprising the composition.
- the kit may further include a lysis buffer or a protease for lysing the cells in the sample to release the nucleic acid from inside the cell, and a buffer for pH adjustment required for effective nucleic acid extraction. It may additionally be included.
- the present invention also provides a composition for microbial enrichment and nucleic acid extraction comprising diatomaceous earth modified with a silane compound as an active ingredient.
- the silane compound may be a compound represented by the following Chemical Formula 1, but is not limited thereto.
- R 1 to R 3 may each be the same or different, either C1 to C4 alkyl or C1 to C4 alkoxy, R 4 is amino (C1 to C10) alkyl, 3- (2-amino ( C1 to C4) alkylamino) (C1 to C4) alkyl or 3- [2- (2-amino (C1 to C4) alkylamino) (C1 to C4) alkylamino] (C1 to C4) alkyl.
- the silane compound is most suitable for (3-aminopropyl) triethoxysilane (APTES) described in the embodiment of the present invention.
- APTES (3-aminopropyl) triethoxysilane
- the microorganism may be any negatively charged microorganism such as bacteria, viruses or cells, and more preferably Brucella ovis or para influenza virus (PIV3) described in the embodiment of the present invention.
- PIV3 para influenza virus
- the concentration of the microorganism may be 10 0 cfu / ml to 10 7 cfu / ml, but is not limited thereto.
- the composition is dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS) and dimethyl 3,3'-dity It may further comprise the step of reacting by adding any one or more selected from the group consisting of dimethyl propionimate (Dimethyl 3,3'-dithiobispropionimidate; DTBP).
- DMA dimethyl adipimidate
- DMP dimethyl pimelimidate
- DMS dimethyl suberimidate
- DTBP dimethyl 3,3'-dity
- the nucleic acid may be DNA or RNA, but is not limited thereto.
- the present invention comprises the steps of (1) contacting the sample containing the microorganism to the diatomaceous earth modified with the silane compound to concentrate the microorganism; (2) dissolving the concentrated microorganism; And (3) eluting the nucleic acid from the lysate, and providing a method for extracting the nucleic acid from the concentrated microorganism at the same time as the microorganism is concentrated.
- the present invention comprises the steps of (1) contacting the sample containing the microorganism to the diatomaceous earth modified with the silane compound to concentrate the microorganism; (2) dissolving the concentrated microorganism; (3) dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS) and dimethyl 3,3'-diti in the lysate Reacting by adding any one or more selected from the group consisting of dimethyl 3,3'-dithiobispropionimidate (DTBP); And (4) provides a method for extracting nucleic acid from the concentrated microorganism simultaneously with the concentration of the microorganism comprising eluting the nucleic acid from the reaction.
- DMA dimethyl adipimidate
- DMP dimethyl pimelimidate
- DMS dimethyl suberimidate
- DTBP dimethyl 3,3'-diti in the lysate Reacting by adding any one or more selected from the group consisting of dimethyl 3,3'-d
- the silane compound may be a compound represented by the following Chemical Formula 1, but is not limited thereto.
- R 1 to R 3 may each be the same or different, either C1 to C4 alkyl or C1 to C4 alkoxy, R 4 is amino (C1 to C10) alkyl, 3- (2-amino ( C1 to C4) alkylamino) (C1 to C4) alkyl or 3- [2- (2-amino (C1 to C4) alkylamino) (C1 to C4) alkylamino] (C1 to C4) alkyl.
- the silane compound is most suitable for (3-aminopropyl) triethoxysilane (APTES) described in the embodiment of the present invention.
- APTES (3-aminopropyl) triethoxysilane
- the sample containing the microorganism is feces, urine, tears, saliva, external secretions of the skin, external secretions of the respiratory tract, external secretions of the intestinal tract, external secretions of the digestive tract, plasma, Serum, blood, spinal fluid, lymph, body fluids and tissues, but are not limited thereto.
- the microorganism may be any negatively charged microorganism such as bacteria, viruses or cells, and more preferably Brucella ovis or para influenza virus (PIV3) described in the embodiment of the present invention.
- PIV3 para influenza virus
- the concentration of the microorganism may be 10 0 cfu / ml to 10 7 cfu / ml, but is not limited thereto.
- the nucleic acid may be DNA or RNA, but is not limited thereto.
- the present invention also provides a microbial enrichment and nucleic acid extraction kit comprising the composition.
- the kit may further include a lysis buffer or a protease for lysing the cells in the sample to release the nucleic acid from inside the cell, and for adjusting the pH required for effective microbial concentration or nucleic acid extraction. Buffers and the like may be additionally included.
- the kit may be in the form of a well-plate, a tube, a column or a microfluidic chip, but the kit may be in the form of any commercially available form. It is possible.
- the well-plate may be manufactured without limitation, such as 96 wells, 384 wells.
- the kit may be a single composition or the individual components of the composition for microbial enrichment or nucleic acid extraction may be stored separately for mixing before use.
- the components of the composition for microbial enrichment or nucleic acid extraction in the kit of the present invention may be packaged separately, or may be packaged in one or more mixtures in any combination of components.
- Each of the individual components or one or more mixtures may be placed in different containers and may comprise the entire kit in a single container.
- the present invention also provides the use of diatomaceous earth modified with a silane compound for microbial enrichment.
- the present invention also provides the use of diatomaceous earth modified with silane compounds for nucleic acid extraction.
- the present invention also provides the use of diatomaceous earth modified with silane compounds for microbial enrichment and nucleic acid extraction.
- Brucella ovis was used as the test pathogen.
- 1 ml of 10 6 cfu / ml Brucella solution was used.
- HCT-116 cancer cells were used as test samples.
- 1 ml of 10 5 cells / ml cell solution was used.
- 100 ⁇ l elution buffer was used for final DNA extraction.
- DNA was extracted using diatomaceous earth (D) and diatomaceous earth (DA) modified with APTES, and dimethyl adipimidate (DMA) was added.
- D diatomaceous earth
- DA diatomaceous earth
- DMA dimethyl adipimidate
- the sample is allowed to react at room temperature until the sample becomes clear (within 1 minute).
- the reaction is carried out at 56 ° C. for 20 minutes to bind DNA to the modified diatomaceous earth (DA).
- DA modified diatomaceous earth
- the mixture is centrifuged for 1 minute using a microcentrifuge. Carefully remove the supernatant.
- the mixture is centrifuged for 1 minute. Using a pipette, transfer the supernatant to a new microtube.
- HCT-116 cell concentration was varied from 10 0 cells / ml to 10 7 cells / ml. As shown in FIG. 10, Q-PCR results showed that DNA extraction was effective even at low cell concentrations.
- HCT-116 cancer cells were used as test samples.
- 1 ml of 10 5 cells / ml cell solution was used.
- 100 ⁇ l elution buffer was used for final RNA extraction.
- RNA extraction ii. 40 ⁇ l of DA was used for RNA extraction.
- HCT-116 cell concentration was varied from 10 1 cells / ml to 10 6 cells / ml.
- Q-PCR results showed that RNA extraction was effective even at low cell concentrations.
- DA diatomaceous earth
- Example 6> for diagnosis Amine Modified Diatomaceous earth based systems (amine-functionalized, diatomaceous earth-based, dimethyl suberimidate assisted system; Application of ADD system
- the ADD system of the present invention was able to successfully extract RNA from biological samples. Compared with traditional analytical methods, the optimized protocol of the ADD system is expected to be useful for nucleic acid-based diagnostics.
- Human brucellosis an endemic disease in many countries and regions, is a worldwide common infectious disease.
- using the ADD system was able to detect even at very low Brucella concentration of 10 0 CFU / mL, which was confirmed that the detection sensitivity is 100 times more improved than the existing kit.
- NTC no-template control
- the ADD system of the present invention further confirmed clinical utility using RNA extracted from 10 5 CFU / mL Brucella samples derived from urine. Since Brucella is a transfection pathogen, we included the same concentration of Brucella in human urine and sheep urine samples. Although the overall Ct value of Brucella in urine was slower than PBS, it was confirmed that the RNA extracted using the ADD system was faster than the RNA extracted using the existing kit (FIG. 16c).
- RNA samples extracted by the ADD system showed faster Ct values compared to existing kits.
- we tested a relatively large volume of samples using the ADD system increasing the detection limit by loading more samples.
- using the ADD system was able to extract more RNA from a large volume (1 mL) sample compared to using the other system (Fig.
- the Ct value for the 1 mL sample derived RNA was about 2 cycles faster than the 200 ⁇ L sample, clearly indicating that the total amount of extracted RNA increased when the sample volume was large.
- the protocol was optimized for 200 ⁇ L samples, the ADD system could also be used for RNA extraction of large volume samples. Therefore, the ADD system proposed in the present invention can be usefully used for RNA extraction and pathogen detection based on nucleic acid amplification by RT-qPCR.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un procédé de concentration microbienne au moyen de diatomite et un procédé d'extraction d'acides nucléiques. Une technique a été mise au point, qui permet d'atteindre environ de 4 à 8 fois la concentration microbienne au moyen de diatomite lorsqu'elle est comparée à l'état de la technique, et un procédé a été mis au point, qui permet d'extraire directement des acides nucléiques de micro-organismes concentrés au moyen de diméthyl adipimidate (DMA) ou analogue. Il est prévu que les techniques de concentration microbienne et d'extraction d'acides nucléiques admissibles dans un seul tube réduisent de manière significative la contamination provenant de l'extérieur, les coûts, le temps, la complexité et autres.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18767296.9A EP3597773A4 (fr) | 2017-03-15 | 2018-03-14 | Procédé de concentration microbienne au moyen de diatomite et procédé d'extraction d'acides nucléiques |
US16/492,606 US20210079374A1 (en) | 2017-03-15 | 2018-03-14 | Microbial concentration method using diatomite and nucleic acid extraction method |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0032581 | 2017-03-15 | ||
KR20170032581 | 2017-03-15 | ||
KR1020180028131A KR102136694B1 (ko) | 2017-03-15 | 2018-03-09 | 규조토를 이용한 미생물 농축 방법 및 핵산 추출 방법 |
KR10-2018-0028131 | 2018-03-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018169307A1 true WO2018169307A1 (fr) | 2018-09-20 |
Family
ID=63522371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/002994 WO2018169307A1 (fr) | 2017-03-15 | 2018-03-14 | Procédé de concentration microbienne au moyen de diatomite et procédé d'extraction d'acides nucléiques |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018169307A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115791716A (zh) * | 2022-09-19 | 2023-03-14 | 河北科技大学 | 蛋白核小球藻荧光检测扑灭通生物毒性的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100239679A1 (en) * | 2007-10-02 | 2010-09-23 | World Minerals, Inc. | Enhanced retention capabilities through methods comprising surface treatment of functional particulate carrier materials, and functional particulate carrier materials made therefrom |
KR20130106743A (ko) * | 2012-03-20 | 2013-09-30 | 한국에너지기술연구원 | 점토를 이용한 미생물로부터 오일 추출 및 오일 생산방법 |
KR20150096444A (ko) * | 2012-12-13 | 2015-08-24 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 고형상 장치 상에서 핵산을 분리 및 분석하는 무표지 방법 |
US20160215325A1 (en) * | 2008-12-31 | 2016-07-28 | 3M Innovative Properties Company | Sampling devices and methods for concentrating microorganisms |
-
2018
- 2018-03-14 WO PCT/KR2018/002994 patent/WO2018169307A1/fr unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100239679A1 (en) * | 2007-10-02 | 2010-09-23 | World Minerals, Inc. | Enhanced retention capabilities through methods comprising surface treatment of functional particulate carrier materials, and functional particulate carrier materials made therefrom |
US20160215325A1 (en) * | 2008-12-31 | 2016-07-28 | 3M Innovative Properties Company | Sampling devices and methods for concentrating microorganisms |
KR20130106743A (ko) * | 2012-03-20 | 2013-09-30 | 한국에너지기술연구원 | 점토를 이용한 미생물로부터 오일 추출 및 오일 생산방법 |
KR20150096444A (ko) * | 2012-12-13 | 2015-08-24 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 고형상 장치 상에서 핵산을 분리 및 분석하는 무표지 방법 |
Non-Patent Citations (2)
Title |
---|
MIGLIACCIO, N.: "Biosilica Nanovector from Diatomite for siRNA Transport in Cancer Cell, thesis", 2015, University of Naples Federico II, Molecular Medicine and Medical Biotechnology, pages 1 - 36, XP055548143 * |
See also references of EP3597773A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115791716A (zh) * | 2022-09-19 | 2023-03-14 | 河北科技大学 | 蛋白核小球藻荧光检测扑灭通生物毒性的方法 |
CN115791716B (zh) * | 2022-09-19 | 2023-07-21 | 河北科技大学 | 一种蛋白核小球藻荧光检测扑灭通生物毒性的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0918877B1 (fr) | Procedes d'isolement d'acides nucleiques a l'aide de protease alcaline | |
US7611837B2 (en) | Kit for detecting non-pathogenic or pathogenic influenza a subtype h5 virus | |
CN108410951B (zh) | 一种新的核酸提取试剂及其应用 | |
US20230227505A1 (en) | Identification and application of alv-j mhc-b2 restrictive epitope peptide | |
WO2019221537A1 (fr) | Procédé de détection de mycoplasme à l'aide d'adn mitochondrial en tant qu'échantillon témoin interne | |
WO2021141369A1 (fr) | Procédé de détection d'arn à base de sonde d'adn simple brin | |
Wagter et al. | PCR detection of lentiviral GAG segment DNA in the white blood cells of sheep and goats | |
Mazalovska et al. | Detection of serum antibodies to hepatitis E virus based on HEV genotype 3 ORF2 capsid protein expressed in nicotiana benthamiana | |
RU2360972C1 (ru) | Способ детекции и определения биотипа, серогруппы и токсигенности возбудителя холеры и набор для его осуществления | |
WO2018169307A1 (fr) | Procédé de concentration microbienne au moyen de diatomite et procédé d'extraction d'acides nucléiques | |
WO2011071259A2 (fr) | Procédé de culture de cellules exemptes de contamination par mycoplasmes et procédé permettant de supprimer, sur des cellules, une contamination par mycoplasmes | |
KR102136694B1 (ko) | 규조토를 이용한 미생물 농축 방법 및 핵산 추출 방법 | |
WO2009093856A2 (fr) | Ensemble d'amorces de pcr pour la détection de mycoplasme dans des produits médicinaux biologiques, et kit pour la détection de mycoplasme comprenant ledit ensemble | |
Sekeyová et al. | Isolation of Rickettsia helvetica from ticks in Slovakia | |
WO2011069398A1 (fr) | Procédé pour la détection rapide d'acide nucléique basé sur qcm et lamp | |
WO2022071648A1 (fr) | Composition de concentration de micro-organisme ou d'extraction d'acide nucléique et procédé de concentration de micro-organisme ou d'extraction d'acide nucléique l'utilisant | |
WO2020116815A1 (fr) | Protéine antigénique de parvovirus porcin recombinante et son utilisation | |
JP2675564B2 (ja) | 急性呼吸疾患に関連する独特のクラミジア株の検出 | |
WO2017200249A1 (fr) | Procédé d'extraction d'acide nucléique utilisant un sujet solide | |
WO2018038549A1 (fr) | Procédé de concentration de micro-organismes ou d'extraction d'acide nucléique à l'aide de dtbp | |
WO2019088429A1 (fr) | Procédé d'extraction d'un biomatériau issu d'une biopsie liquide à l'aide d'imidoester homobifonctionnel | |
WO2019225791A1 (fr) | Sonde mlpa pour la détection de bactéries gram-négatives induisant une septicémie, et son utilisation | |
WO2019088527A2 (fr) | Procédé de lyse de pathogènes et d'extraction d'acides nucléiques à l'aide de nanoétoiles d'oxyde de zinc | |
CN106916894A (zh) | 一种多重pcr检测微生态活菌制剂中食源性致病菌的方法 | |
WO2022154214A1 (fr) | Composition tampon pour isolement d'acide nucléique pour pcr à tube unique sous forme de colonne et utilisation associée |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18767296 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018767296 Country of ref document: EP Effective date: 20191015 |